US President Trump directs stockpiling of APIs for 26 critical drugs, reinforcing domestic pharma manufacturing and strengthening the US pharma supply chain.
The FDA has approved DAWNZERA for hereditary angioedema patients, offering the first RNA-targeted therapy designed to prevent HAE attacks with durable efficacy.
The FDA PreCheck programme will streamline regulations, boost U.S. drug manufacturing, and strengthen resilience in the domestic pharmaceutical supply chain.
J&J Investment of $2B expands U.S. drug manufacturing capacity, enhances production of advanced medicines, and strengthens healthcare innovation nationwide.
Roche breaks ground on a Genentech Manufacturing Facility in USA's North Carolina, expanding production of metabolic medicines and creating new jobs in USA.
